Arrowhead Pharma (ARWR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 09/30
| 09-2005 | 09-2004 | 09-2003 | 09-2002 | 09-2001 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -6,855 | -2,529 | -95 | -246 | -186 |
| Depreciation Amortization | 644 | 75 | 0 | 9 | 4 |
| Accounts receivable | 18 | -52 | N/A | 1 | 1 |
| Accounts payable and accrued liabilities | -69 | 248 | 93 | 37 | 4 |
| Other Working Capital | 445 | 41 | -62 | 183 | 152 |
| Other Operating Activity | -3,283 | -98 | -93 | -89 | -56 |
| Operating Cash Flow | $-9,099 | $-2,314 | $-158 | $-106 | $-82 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 51 | N/A | N/A | N/A | N/A |
| PPE Investments | -673 | -666 | -2 | -2 | N/A |
| Sale Of Investment | 2,915 | N/A | N/A | N/A | N/A |
| Purchase Sale Intangibles | -98 | N/A | N/A | N/A | N/A |
| Other Investing Activity | -23 | 306 | 0 | 0 | 0 |
| Investing Cash Flow | $2,269 | $-360 | $-2 | $-2 | $N/A |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | N/A | 100 | N/A |
| Debt Repayment | N/A | N/A | N/A | -6 | -4 |
| Common Stock Issued | 20,744 | 9,871 | 1,515 | N/A | N/A |
| Other Financing Activity | 0 | 0 | 0 | 31 | 84 |
| Financing Cash Flow | $20,744 | $9,871 | $1,515 | $126 | $80 |
| Beginning Cash Position | 8,553 | 1,355 | N/A | 0 | 2 |
| End Cash Position | 22,467 | 8,553 | 1,355 | 19 | 0 |
| Net Cash Flow | $13,914 | $7,197 | $1,355 | $18 | $-2 |
| Free Cash Flow | |||||
| Operating Cash Flow | -9,099 | -2,314 | -158 | -106 | -82 |
| Capital Expenditure | -673 | -666 | -2 | -2 | N/A |
| Free Cash Flow | -9,772 | -2,980 | -160 | -108 | -82 |